IN June 2026, The Nature Index, one of the most well-regarded barometers of high-quality research, issued the annual Research Leaders rankings. It made the academic community sit up and take note. Harvard University slid from first place to third for the first time in 10 years, behind China's Zhejiang University and the Chinese Academy of Sciences. Chinese institutions now occupy nine of the top 10 overall slots. This would have been unimaginable 20 years ago. Today it is only the clearest expression yet of one of the most profound revolutions in the geopolitics of research.

But to get a sense of this transformation, you have to look beyond the rankings themselves. As Leon Liao's concept "China as a System" suggests, China's rise cannot be explained by ideology, headline GDP or diplomatic confrontation alone. It has to be understood through factories, grids, ports, local governments, State-Owned Enterprises (SOEs), private enterprises, engineers, supply chains and the institutional structures that turn resources into capability. That is the broader context for comprehending what China has done.

STATE LONG-TERM INVESTMENT

China's ascent is not a flash in the pan. It is the result of continual and systematic investment over twenty years. In 2000, China's gross R&D spending was just $40.8 billion. By 2024, it had risen to roughly $786 billion - a nineteenfold increase. China was the world's largest R&D investor, accounting for around 27 per cent of worldwide investment. Its R&D investment was 2.7 per cent of GDP in 2024, with an average annual growth rate of 4.1 per cent since 2004. That funding has created output. China's share of the Nature Index grew by 22.4 per cent year-on-year in 2025, compared with 4.2 per cent for the United States.

China's strategy is distinct not just in the amount of investment, but also in how it is organised. China as a System demonstrates how Chinese institutions - from central government ministries to provincial authorities to SOEs and private firms - function in a well-orchestrated manner to turn resources into deployable capabilities. It is not a market process in the Western sense, nor a totally command economy. This is a system which we see now work extremely well at scale - with state capability, capital accumulation, and technical spread reinforcing each other in a variety of ways.

Sceptics derided China's scientific rise as one of quantity,  not of quality: more articles, but not necessarily better ones. The numbers tell another story. By August 2025, China had 2,342 "hot papers" (research that has earned extraordinarily high citation counts), or 53.2% of the world's total, compared to 1,511 for the United States. China also published 76,271 highly referenced articles, or 37.4 per cent of the world total, and the margin between it and the United States was narrowed to a mere handful of papers! It is number one in applied sciences and chemistry and has nine of the top ten institutions in earth and environmental sciences.

According to the Australian Strategic Policy Institute's 2025 Critical Technology Tracker, China leads in 66 of the 74 critical technologies, including nuclear power, synthetic biology and tiny satellites. The United States leads in just eight, including quantum computing and geoengineering. Even in that, China is moving ahead fast. In 2025, Chinese company OriginQC delivered a 24-qubit (quantum bit) superconducting quantum computer to a commercial client with a local supply chain and operating system. Yuanxin Quantum, a spin-off of the Chinese Academy of Sciences, has a 198-qubit neutral-atom quantum computer on the market, making China one of the first nations to provide that architecture over the cloud. The United States still leads in private capital and has an edge with IBM, Google and QuEra; however, China's dual-track hardware approach demonstrates how continuous state investment can turn a follower into a genuine challenger, a pattern seen across the Nature Index. At the start of this century, the United States led in more than 90 per cent of the technologies measured by ASPI, while China's share was less than 5 per cent.

TRANSLATIONAL SCIENCE

Beijing's strategy is an example of how systematically China is closing the "valley of death" between lab research and commercial viability. Universities, start-ups, industry and the state are in a closed loop with public funding and infrastructure in places like Zhongguancun and Yizhuang encouraging high-risk, long-term initiatives. That similar strategy now guides China's advancement of AI and humanoid robotics, from research into everyday innovation.

But the actual measure of scientific advancement is not rankings or citations, but whether science improves human lives. China's record here is significant, too. In January, the country's National Medical Products Administration conditionally approved the country's first stem cell therapy. This was from research at Tsinghua University, for a life-threatening consequence of bone marrow transplants. In August 2025, Shanghai-based CorrectSequence Therapeutics said it had achieved what it claimed was the first clinical treatment of sickle cell disease in China, utilising a process known as "base editing" that precisely edits a single nucleotide base in the target DNA. In another instance, Chinese doctors employed gene-editing technology to treat a four-year-old Pakistani child suffering from beta thalassemia who returned home cured following therapy in Shanghai in May 2025. Chinese researchers have also turned the spleen into a bioreactor for treatment of diabetes and organ growth. This was described in the journal Science Translational Medicine. It has only worked in mice and monkeys to date, but is a promising preclinical platform and indicates the potential. And there's a pipeline of such medications reaching patients or with research only a few years away from the clinic.

GLOBAL COMPARISON

The disparity between the United States and Europe is huge. The West still produces the most science, but is increasing slowly or not at all, while China continues to grow at double-digit rates. This transition has been quantified in the way multinational scientific teams are being directed, as evidenced by a recent study published in the journal Proceedings of the National Academy of Sciences USA (PNAS) in October 2025. The study investigated approximately 6 million bilateral collaborations and found that in 2023 Chinese institutions accounted for up to 45% of lead teams in US-China collaborations, a massive rise from 30% in 2010. In fact, the model predicts that by 2027-28, China's absolute share of leadership roles in collaborative teams might match that of the United States. But the rise is not restricted to low-impact journals or mid-level jobs. The researchers found China is on pace to match the United States in leadership across all journal impact factor tiers, including at the top levels.

Furthermore, by 2030, China is anticipated to have an equal share of leadership in 8 out of 11 essential technologies recognised by the United States National Science Foundation, including Artificial Intelligence (AI), semiconductors, and energy technologies. The study says China is not only the world's biggest creator of high-quality research. It is also an increasingly dominant organiser of global scientific labour, calling China's evolution over the previous two decades "remarkable". Clarivate, a renowned provider of informatics services, examined 25 years of data from Web of Science and found that China's output has more than doubled over the previous decade, surpassing the US to become the world's greatest producer of research papers in 2020.

But India is another matter. India's flagship institution, the Indian Institute of Science, was only ranked 202nd in the 2026 Nature Index, with India in eighth position among countries worldwide behind China. That disparity is not a skill gap; it's about decades of underinvestment institutionally.

What the past twenty years have shown us is that scientific leadership is not a birthright. It requires deliberate strategy, consistent investment, and a national vision that places research at the centre of development. China's climb in the Nature Index, its dominance in crucial technologies and its discoveries in biotech and AI are not accidents, but the harvest of seeds sown two decades ago. Yet the bigger lesson is: science at its best is not about rankings or national pride. It is about making life better. In this respect, China's scientific ascent is already paying dividends. Its rise is undeniable. The only question is whether the rest of the world is wise enough to learn from it—or foolish enough to look away.